首页 > 最新文献

Urologie最新文献

英文 中文
AUO.
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 DOI: 10.1007/s00120-024-02496-z
{"title":"AUO.","authors":"","doi":"10.1007/s00120-024-02496-z","DOIUrl":"https://doi.org/10.1007/s00120-024-02496-z","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":"64 1","pages":"100-101"},"PeriodicalIF":0.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GeSRU.
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 DOI: 10.1007/s00120-024-02498-x
{"title":"GeSRU.","authors":"","doi":"10.1007/s00120-024-02498-x","DOIUrl":"https://doi.org/10.1007/s00120-024-02498-x","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":"64 1","pages":"97-99"},"PeriodicalIF":0.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Enfortumab vedotin and pembrolizumab : Management of side effects during first line combined treatment for advanced or metastatic urothelial carcinoma]. [恩多单抗和派姆单抗:一线联合治疗晚期或转移性尿路上皮癌的副作用管理]。
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 Epub Date: 2025-01-07 DOI: 10.1007/s00120-024-02487-0
Margitta Retz, Marc-Oliver Grimm, Katharina Leucht, Stefanie Zschäbitz

The aim of this article is to raise awareness among healthcare providers about the adverse events (AEs) associated with the combined treatment with enfortumab vedotin and pembrolizumab. The differential diagnostic allocation of these AEs to the respective agents is discussed, overlaps between the side effect profiles of the two drugs are identified and strategies for an effective management of these AEs are presented. The recommendations are based on the currently valid prescription information for both drugs, the results of pivotal approval studies and the guidelines of recognized specialist organizations as well as the clinical experience of the authors.

本文的目的是提高医疗保健提供者对与强制维多单抗和派姆单抗联合治疗相关的不良事件(ae)的认识。讨论了这些不良反应的不同诊断分配,确定了两种药物的副作用概况之间的重叠,并提出了有效管理这些不良反应的策略。这些建议是基于两种药物目前有效的处方信息、关键批准研究的结果、公认的专家组织的指南以及作者的临床经验。
{"title":"[Enfortumab vedotin and pembrolizumab : Management of side effects during first line combined treatment for advanced or metastatic urothelial carcinoma].","authors":"Margitta Retz, Marc-Oliver Grimm, Katharina Leucht, Stefanie Zschäbitz","doi":"10.1007/s00120-024-02487-0","DOIUrl":"10.1007/s00120-024-02487-0","url":null,"abstract":"<p><p>The aim of this article is to raise awareness among healthcare providers about the adverse events (AEs) associated with the combined treatment with enfortumab vedotin and pembrolizumab. The differential diagnostic allocation of these AEs to the respective agents is discussed, overlaps between the side effect profiles of the two drugs are identified and strategies for an effective management of these AEs are presented. The recommendations are based on the currently valid prescription information for both drugs, the results of pivotal approval studies and the guidelines of recognized specialist organizations as well as the clinical experience of the authors.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"60-74"},"PeriodicalIF":0.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Berufspolitik BvDU. Berufspolitik BvDU .
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 DOI: 10.1007/s00120-024-02504-2
{"title":"Berufspolitik BvDU.","authors":"","doi":"10.1007/s00120-024-02504-2","DOIUrl":"https://doi.org/10.1007/s00120-024-02504-2","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":"64 1","pages":"85-96"},"PeriodicalIF":0.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Comorbidities after radical prostatectomy : Which subjective health restrictions are relevant for long-term survivors?] [前列腺癌根治术后的并发症:哪些主观健康限制与长期幸存者相关?]
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 Epub Date: 2024-09-20 DOI: 10.1007/s00120-024-02441-0
Tobiasz Klorek, Anton N J H Schlichte, Cornelia Peter, Matthias Jahnen, Andreas Dinkel, Stefan Schiele, Lukas Lunger, Helga Schulwitz, Jürgen E Gschwend, Kathleen Herkommer

Background: Radical prostatectomy (RP) is one of the most common therapeutic strategies for treating localized prostate cancer (PCa). Currently, the significance of postoperative functional limitations for affected patients in the long-term course, especially in comparison to age-related comorbidities, is unclear.

Objective: The aim of this study was to quantify the prevalence of subjective health restrictions alongside functional deficits in long-term PCa survivors after RP and their relevance for subjective impairments in everyday life.

Materials and methods: Using the German version of the Self-Administered Comorbidity Questionnaire (SCQ-D), 3173 long-term survivors after RP reported their comorbidities in 13 predefined categories and in 3 free-text fields along the dimensions "problem," "treatment," and "impairment".

Results: The mean age at survey was 79.5 years (standard deviation, SD ± 6.4), with a mean time since RP of 17.4 years (SD ± 3.7). The three most frequently identified comorbidities/percentage of patients who felt impaired were: hypertension (62.2%/8.5%), back pain (44.1%/54.5%), and osteoarthritis (36.1%/54.1%). The most frequently mentioned additional health problems can be subsumed under the umbrella term "urological problems" (6.1%/72.7%): incontinence (4.8%/74.3%), bladder problems (1.1%/61.8%), and erectile dysfunction (0.5%/47.1%).

Conclusion: In summary, non-cancer-related comorbidities in the long-term course after RP are often perceived as "problems" but rarely lead to subjective impairment. In contrast, treatment-related urological problems are rarely reported as "problems", but they very often lead to subjective impairment in everyday life.

背景:根治性前列腺切除术(RP)是治疗局部前列腺癌(PCa)最常见的治疗策略之一。目前,受影响患者术后长期功能受限的意义尚不明确,尤其是与年龄相关的合并症相比:本研究旨在量化 PCa 术后长期存活者的主观健康限制与功能障碍的发生率,以及它们与日常生活中主观障碍的相关性:使用德文版自编合并症问卷(SCQ-D),3173名RP术后长期存活者按照 "问题"、"治疗 "和 "损伤 "三个维度,在13个预定义类别和3个自由文本字段中报告了他们的合并症:调查时的平均年龄为 79.5 岁(标准差,SD ± 6.4),RP 后的平均时间为 17.4 年(SD ± 3.7)。最常见的三种合并症/感觉受损的患者比例分别为:高血压(62.2%/8.5%)、背痛(44.1%/54.5%)和骨关节炎(36.1%/54.1%)。最常提及的其他健康问题可归纳为 "泌尿系统问题"(6.1%/72.7%):尿失禁(4.8%/74.3%)、膀胱问题(1.1%/61.8%)和勃起功能障碍(0.5%/47.1%):总之,在 RP 术后的长期病程中,与癌症无关的合并症通常被视为 "问题",但很少导致主观功能障碍。与此相反,与治疗相关的泌尿系统问题很少被报告为 "问题",但却经常导致日常生活中的主观障碍。
{"title":"[Comorbidities after radical prostatectomy : Which subjective health restrictions are relevant for long-term survivors?]","authors":"Tobiasz Klorek, Anton N J H Schlichte, Cornelia Peter, Matthias Jahnen, Andreas Dinkel, Stefan Schiele, Lukas Lunger, Helga Schulwitz, Jürgen E Gschwend, Kathleen Herkommer","doi":"10.1007/s00120-024-02441-0","DOIUrl":"10.1007/s00120-024-02441-0","url":null,"abstract":"<p><strong>Background: </strong>Radical prostatectomy (RP) is one of the most common therapeutic strategies for treating localized prostate cancer (PCa). Currently, the significance of postoperative functional limitations for affected patients in the long-term course, especially in comparison to age-related comorbidities, is unclear.</p><p><strong>Objective: </strong>The aim of this study was to quantify the prevalence of subjective health restrictions alongside functional deficits in long-term PCa survivors after RP and their relevance for subjective impairments in everyday life.</p><p><strong>Materials and methods: </strong>Using the German version of the Self-Administered Comorbidity Questionnaire (SCQ-D), 3173 long-term survivors after RP reported their comorbidities in 13 predefined categories and in 3 free-text fields along the dimensions \"problem,\" \"treatment,\" and \"impairment\".</p><p><strong>Results: </strong>The mean age at survey was 79.5 years (standard deviation, SD ± 6.4), with a mean time since RP of 17.4 years (SD ± 3.7). The three most frequently identified comorbidities/percentage of patients who felt impaired were: hypertension (62.2%/8.5%), back pain (44.1%/54.5%), and osteoarthritis (36.1%/54.1%). The most frequently mentioned additional health problems can be subsumed under the umbrella term \"urological problems\" (6.1%/72.7%): incontinence (4.8%/74.3%), bladder problems (1.1%/61.8%), and erectile dysfunction (0.5%/47.1%).</p><p><strong>Conclusion: </strong>In summary, non-cancer-related comorbidities in the long-term course after RP are often perceived as \"problems\" but rarely lead to subjective impairment. In contrast, treatment-related urological problems are rarely reported as \"problems\", but they very often lead to subjective impairment in everyday life.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"29-37"},"PeriodicalIF":0.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Knowledge about human papillomaviruses among students in Germany-a cross-sectional study with a need for action]. [德国学生对人类乳头瘤病毒的了解--一项需要采取行动的横断面研究]。
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 Epub Date: 2024-08-29 DOI: 10.1007/s00120-024-02436-x
Cem Aksoy, Laila Schneidewind, Marius Butea-Bocu, Philipp Reimold, Sandra Schönburg, Johannes Huber, Radu Alexa, Matthias Saar, Jennifer Kranz

Background and objectives: The human papillomavirus (HPV) is one of the most common viruses transmitted through intimate contact, causing many benign and malignant diseases. Vaccination protects against these diseases. Despite the HPV vaccination being recommended by the Standing Committee on Vaccination (STIKO), knowledge and vaccination rates in Germany are very low. Therefore, the aim of the study was to assess the HPV knowledge among German students.

Materials and methods: Between 06/2019 and 01/2024, a nationwide online survey on HPV knowledge among students in Germany was distributed via the respective student councils. The survey included two aspects: 1) basic characteristics of the participants and 2) knowledge questions about HPV (e.g., transmission routes, effectiveness, and side effects of vaccination, knowledge about the HPV subtypes). Data collection was anonymous.

Results: A total of 459 students took part in the study. Of these, 335 (72.98%) were female, 122 (26.57%) were male, and 2 (0.45%) did not specify their gender. The average age of the students was 24.02 years, and most of the participants were in their 6th (23.31%/107) semester. In all, 75.82% (348) of the participants were medical students followed by law students with 19.61% (90) participants. The most represented study location was Aachen, with 270 (58.82%) participants. Only about half (48.80%/223) of the students knew that approximately 8000 new cancer cases in Germany are HPV-associated annually. Regarding the HPV vaccination, more than a third (35.82%/163) of participants did not know that it also protects against genital warts, while 21.93% (100) did not know that boys can also benefit from the HPV vaccination and that it does not only improve HPV protection of girls against cervical cancer.

Conclusion: Despite several years of HPV vaccination recommendation by the Standing Committee on Vaccination (STIKO), knowledge about HPV among college students still remains very low. Further prevention and educational efforts are needed to address HPV knowledge gaps, with the additional goal of improving HPV vaccination rates.

背景和目的:人类乳头瘤病毒(HPV)是通过亲密接触传播的最常见病毒之一,可导致多种良性和恶性疾病。接种疫苗可预防这些疾病。尽管疫苗接种常设委员会(STIKO)推荐接种 HPV 疫苗,但德国的疫苗接种知识和接种率都非常低。因此,本研究旨在评估德国学生对人类乳头瘤病毒(HPV)的了解程度:在 2019 年 6 月至 2024 年 1 月期间,通过各学生会对德国学生进行了一次关于 HPV 知识的全国性在线调查。调查包括两个方面:1)参与者的基本特征;2)关于HPV的知识问题(如传播途径、疫苗接种的有效性和副作用、对HPV亚型的了解)。数据收集采用匿名方式:共有 459 名学生参加了研究。结果:共有 459 名学生参加了研究,其中 335 人(72.98%)为女性,122 人(26.57%)为男性,2 人(0.45%)未注明性别。学生的平均年龄为 24.02 岁,大多数参与者是六年级学生(23.31%/107)。总共有 75.82%(348 人)的参与者是医科学生,其次是法科学生,占 19.61%(90 人)。参与人数最多的研究地点是亚琛,有 270 人(58.82%)参与。只有约一半(48.80%/223)的学生知道德国每年约有 8000 例新的癌症病例与人乳头瘤病毒有关。关于 HPV 疫苗接种,超过三分之一(35.82%/163 人)的参与者不知道它还能预防生殖器疣,而 21.93%(100 人)的参与者不知道男孩也能从 HPV 疫苗接种中受益,也不知道 HPV 疫苗接种不仅能提高女孩预防宫颈癌的能力:尽管疫苗接种常设委员会(STIKO)推荐接种 HPV 疫苗已有数年之久,但大学生对 HPV 的了解程度仍然很低。需要进一步开展预防和教育工作,解决 HPV 知识缺口问题,同时提高 HPV 疫苗接种率。
{"title":"[Knowledge about human papillomaviruses among students in Germany-a cross-sectional study with a need for action].","authors":"Cem Aksoy, Laila Schneidewind, Marius Butea-Bocu, Philipp Reimold, Sandra Schönburg, Johannes Huber, Radu Alexa, Matthias Saar, Jennifer Kranz","doi":"10.1007/s00120-024-02436-x","DOIUrl":"10.1007/s00120-024-02436-x","url":null,"abstract":"<p><strong>Background and objectives: </strong>The human papillomavirus (HPV) is one of the most common viruses transmitted through intimate contact, causing many benign and malignant diseases. Vaccination protects against these diseases. Despite the HPV vaccination being recommended by the Standing Committee on Vaccination (STIKO), knowledge and vaccination rates in Germany are very low. Therefore, the aim of the study was to assess the HPV knowledge among German students.</p><p><strong>Materials and methods: </strong>Between 06/2019 and 01/2024, a nationwide online survey on HPV knowledge among students in Germany was distributed via the respective student councils. The survey included two aspects: 1) basic characteristics of the participants and 2) knowledge questions about HPV (e.g., transmission routes, effectiveness, and side effects of vaccination, knowledge about the HPV subtypes). Data collection was anonymous.</p><p><strong>Results: </strong>A total of 459 students took part in the study. Of these, 335 (72.98%) were female, 122 (26.57%) were male, and 2 (0.45%) did not specify their gender. The average age of the students was 24.02 years, and most of the participants were in their 6th (23.31%/107) semester. In all, 75.82% (348) of the participants were medical students followed by law students with 19.61% (90) participants. The most represented study location was Aachen, with 270 (58.82%) participants. Only about half (48.80%/223) of the students knew that approximately 8000 new cancer cases in Germany are HPV-associated annually. Regarding the HPV vaccination, more than a third (35.82%/163) of participants did not know that it also protects against genital warts, while 21.93% (100) did not know that boys can also benefit from the HPV vaccination and that it does not only improve HPV protection of girls against cervical cancer.</p><p><strong>Conclusion: </strong>Despite several years of HPV vaccination recommendation by the Standing Committee on Vaccination (STIKO), knowledge about HPV among college students still remains very low. Further prevention and educational efforts are needed to address HPV knowledge gaps, with the additional goal of improving HPV vaccination rates.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"38-46"},"PeriodicalIF":0.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Indications regarding early detection screening for genital tract neoplasms]. [生殖道肿瘤早期检测筛查的适应症]。
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 Epub Date: 2024-11-12 DOI: 10.1007/s00120-024-02477-2
Pia Paffenholz

Background: Testicular tumors and penile cancer are rare but potentially life-threatening diseases. Testicular tumors primarily affect younger men, while penile cancer is more common in older men. Early detection can significantly improve survival rates.

Objectives: This article investigates the indications for early detection screenings for testicular tumors and penile cancer.

Methods: A comprehensive literature review was conducted to analyze current studies and guidelines.

Results: No general screening programs are recommended for either type of cancer. For testicular tumors, self-examination of the testes is recommended, while for penile carcinomas, education on risk factors such as human papillomavirus (HPV) infections or phimosis is emphasized. In both cases, medical examination is crucial.

Conclusion: Education and awareness, especially among at-risk groups, are essential. Physicians play a key role in conducting and recommending early detection measures.

背景:睾丸肿瘤和阴茎癌是罕见但可能危及生命的疾病。睾丸肿瘤主要影响年轻男性,而阴茎癌则更常见于老年男性。早期发现可大大提高生存率:本文研究了睾丸肿瘤和阴茎癌早期检测筛查的适应症:方法:对目前的研究和指南进行了全面的文献综述分析:结果:对于这两种癌症,均未推荐进行常规筛查。对于睾丸肿瘤,建议对睾丸进行自我检查,而对于阴茎癌,则强调有关风险因素的教育,如人类乳头瘤病毒(HPV)感染或包皮过长。在这两种情况下,医学检查都至关重要:结论:教育和宣传,尤其是对高危人群的教育和宣传至关重要。医生在开展和建议早期检测措施方面发挥着关键作用。
{"title":"[Indications regarding early detection screening for genital tract neoplasms].","authors":"Pia Paffenholz","doi":"10.1007/s00120-024-02477-2","DOIUrl":"10.1007/s00120-024-02477-2","url":null,"abstract":"<p><strong>Background: </strong>Testicular tumors and penile cancer are rare but potentially life-threatening diseases. Testicular tumors primarily affect younger men, while penile cancer is more common in older men. Early detection can significantly improve survival rates.</p><p><strong>Objectives: </strong>This article investigates the indications for early detection screenings for testicular tumors and penile cancer.</p><p><strong>Methods: </strong>A comprehensive literature review was conducted to analyze current studies and guidelines.</p><p><strong>Results: </strong>No general screening programs are recommended for either type of cancer. For testicular tumors, self-examination of the testes is recommended, while for penile carcinomas, education on risk factors such as human papillomavirus (HPV) infections or phimosis is emphasized. In both cases, medical examination is crucial.</p><p><strong>Conclusion: </strong>Education and awareness, especially among at-risk groups, are essential. Physicians play a key role in conducting and recommending early detection measures.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"24-28"},"PeriodicalIF":0.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Objectives of screening and early detection in medicine]. 【医学筛查和早期发现的目的】。
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 Epub Date: 2025-01-14 DOI: 10.1007/s00120-024-02488-z
Axel Heidenreich, Peter Albers, Maurice Stephan Michel
{"title":"[Objectives of screening and early detection in medicine].","authors":"Axel Heidenreich, Peter Albers, Maurice Stephan Michel","doi":"10.1007/s00120-024-02488-z","DOIUrl":"https://doi.org/10.1007/s00120-024-02488-z","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":"64 1","pages":"1-3"},"PeriodicalIF":0.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Early detection of prostate cancer-individualized, risk-adapted and successful]. [前列腺癌的早期检测个体化,风险适应和成功]。
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 Epub Date: 2024-11-28 DOI: 10.1007/s00120-024-02478-1
Anne Hübner, Isabelle Bußhoff, Jale Lakes, Rouvier Al-Monajjed, Jan Philipp Radtke, Peter Albers

Background: Population-based screening for prostate cancer (PC) is still controversially discussed. Furthermore, an organized, risk-adapted screening program is already being called for across Europe. Although large randomized controlled trials have shown that prostate-specific antigen (PSA)-based screening can significantly reduce PC-specific mortality, all known screening strategies still frequently lead to overdiagnosis and consecutively to overtreatment of clinically insignificant PC.

Objective: This review article presents the current evidence regarding PC screening.

Results: The current German early detection program, which is based on the annually recommended digital rectal examination (DRE), lacks specificity and sensitivity. In Germany, an opportunistic PSA screening is currently being carried out, which is no longer recommended due to an unfavorable benefit-risk ratio. Since 2022, the European Commission has been calling for the development of organized, risk-adapted screening strategies that combine the PSA test with magnetic resonance imaging (MRI). The integration of MRI improves the detection of clinically relevant PC and reduces the overdiagnosis of low-risk cancers. In the future, an algorithm for early detection of PC needs to be developed, which, in an organized and personalized screening, combines the PSA test with MRI and possibly genetic markers.

Conclusion: The early detection of prostate cancer should be organized at the population level and integrated into personalized, evidence-based screening strategies.

背景:基于人群的前列腺癌筛查(PC)仍有争议的讨论。此外,一项有组织的、适应风险的筛查计划已经在欧洲各地被呼吁。尽管大型随机对照试验表明,基于前列腺特异性抗原(PSA)的筛查可以显著降低PC特异性死亡率,但所有已知的筛查策略仍然经常导致临床无关紧要的PC的过度诊断和过度治疗。目的:本文综述了目前关于PC筛查的证据。结果:目前德国的早期检测方案是基于每年推荐的直肠指检(DRE),缺乏特异性和敏感性。在德国,目前正在进行机会性PSA筛查,由于不利的获益-风险比,不再推荐。自2022年以来,欧盟委员会一直呼吁制定有组织的、适应风险的筛查策略,将PSA检测与磁共振成像(MRI)相结合。MRI的整合提高了临床相关PC的检测,减少了低危癌症的过度诊断。在未来,需要开发一种早期检测PC的算法,在有组织和个性化的筛查中,将PSA测试与MRI和可能的遗传标记结合起来。结论:前列腺癌的早期发现应在人群层面进行组织,并纳入个性化的循证筛查策略。
{"title":"[Early detection of prostate cancer-individualized, risk-adapted and successful].","authors":"Anne Hübner, Isabelle Bußhoff, Jale Lakes, Rouvier Al-Monajjed, Jan Philipp Radtke, Peter Albers","doi":"10.1007/s00120-024-02478-1","DOIUrl":"10.1007/s00120-024-02478-1","url":null,"abstract":"<p><strong>Background: </strong>Population-based screening for prostate cancer (PC) is still controversially discussed. Furthermore, an organized, risk-adapted screening program is already being called for across Europe. Although large randomized controlled trials have shown that prostate-specific antigen (PSA)-based screening can significantly reduce PC-specific mortality, all known screening strategies still frequently lead to overdiagnosis and consecutively to overtreatment of clinically insignificant PC.</p><p><strong>Objective: </strong>This review article presents the current evidence regarding PC screening.</p><p><strong>Results: </strong>The current German early detection program, which is based on the annually recommended digital rectal examination (DRE), lacks specificity and sensitivity. In Germany, an opportunistic PSA screening is currently being carried out, which is no longer recommended due to an unfavorable benefit-risk ratio. Since 2022, the European Commission has been calling for the development of organized, risk-adapted screening strategies that combine the PSA test with magnetic resonance imaging (MRI). The integration of MRI improves the detection of clinically relevant PC and reduces the overdiagnosis of low-risk cancers. In the future, an algorithm for early detection of PC needs to be developed, which, in an organized and personalized screening, combines the PSA test with MRI and possibly genetic markers.</p><p><strong>Conclusion: </strong>The early detection of prostate cancer should be organized at the population level and integrated into personalized, evidence-based screening strategies.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"14-23"},"PeriodicalIF":0.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142751739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Treatment of BK virus infection in kidney transplant patients]. 肾移植患者BK病毒感染的治疗
IF 0.5 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 Epub Date: 2024-12-23 DOI: 10.1007/s00120-024-02491-4
Laila Schneidewind
{"title":"[Treatment of BK virus infection in kidney transplant patients].","authors":"Laila Schneidewind","doi":"10.1007/s00120-024-02491-4","DOIUrl":"10.1007/s00120-024-02491-4","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"47-51"},"PeriodicalIF":0.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Urologie
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1